Healthcare Equipment and Supplies
Company Overview of Bayer HealthCare LLC
Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...
100 Bayer Boulevard
PO Box 915
Whippany, NJ 07981-0915
Founded in 2002
Key Executives for Bayer HealthCare LLC
President and General Manager
President of Worldwide Bayer Consumer Care Division
President of Consumer Care Division
Compensation as of Fiscal Year 2013.
Bayer HealthCare LLC Key Developments
Portola Pharmaceuticals Enters into Clinical Collaboration Agreement with Bayer Healthcare and Janssen Pharmaceuticals, Inc. for Phase 3 Studies of Andexanet Alfa
Feb 3 14
Portola Pharmaceuticals announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare and Janssen Pharmaceuticals, Inc. to evaluate its investigational Factor Xa inhibitor reversal agent, andexanet alfa, in Phase 3 registration studies with the U.S. Food and Drug Administration (FDA)-approved oral Factor Xa inhibitor XARELTO(R) (rivaroxaban). Portola's original collaboration agreement with Bayer and Janssen, announced in February 2013, covered the conduct of a Phase 2 proof-of-concept study. The new clinical collaboration agreement will be in effect through completion of Phase 3 studies with XARELTO(R) and any potential U.S. and EU regulatory approval of andexanet alfa. The Phase 3 studies are expected to start in the first half of 2014. Under this non-exclusive collaboration agreement, Portola will receive an upfront payment and is eligible to receive additional development and regulatory milestone payments. Portola retains full, worldwide commercial rights to andexanet alfa, which was designated as a breakthrough therapy by the FDA in November 2013 and for which Portola is pursuing an Accelerated Approval pathway.
Bayer HealthCare LLC Animal Health Division Introduces Annihilator(TM) Polyzone(R)
Jan 28 14
Bayer HealthCare LLC Animal Health Division has announced the introduction of a broad-spectrum premise spray called Annihilator(TM) Polyzone(R). The product provides livestock producers with long-term control of crawling, flying and wood-infesting pests. Bayer's proprietary technology allows the product to withstand aggressive surfaces, weather and wash-off conditions for up to 90 days. This residual enables users to maintain control with fewer applications which can result in reduced labor. The proprietary technology within Annihilator Polyzone forms a protective layer between the active ingredient particles and the applied area adhering them to the surface. As the Polyzone crystals erode over time, the active ingredient, deltamethrin, is slowly released, leading to effective control for up to 90 days. This residual gives users the ability to apply the product in many areas, as well as hard-to-spray areas.
Bayer HealthCare to Invest in Manufacturing Operations; Announces Restructuring Operations
Jan 20 14
Bayer HealthCare LLC announced that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will invest an estimated $10 million between its Kansas and Missouri sites located in the greater Kansas City region, which is part of the Animal Health Corridor. Bayer will also invest an estimated $3.5 million in its Shawnee site to consolidate and build R&D capabilities. The overall manufacturing operations optimization is expected to be completed early next year.
The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year. Additionally, Bayer will be transferring its regulatory and development activity to its U.S. headquarters based in Shawnee, Kan. by early 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions